Search

Displaying results 1851 - 1860 of 8517 in total
  1. Drug

    Ergocalciferol

    go.drugbank.com/drugs/DB00153
    ApprovedInvestigationalNutraceutical

    Ergocalciferol was isolated for the first time from yeast in 1931 and its structure was elucidated in 1932. … [A177637] The first approved product containing ergocalciferol under the FDA records was developed by US Pharm Holdings and was FDA approved in 1941.[L6058]

  2. Drug

    DaxibotulinumtoxinA

    go.drugbank.com/drugs/DB17929
    ApprovedInvestigational

    [L47865] On August 14, 2023, the drug was also approved for the treatment of cervical dystonia. … [A261075, L47860] DaxibotulinumtoxinA was first approved by the FDA on September 8, 2022, for the temporary improvement of glabellar lines.

  3. Drug

    Stanozolol

    go.drugbank.com/drugs/DB06718
    ApprovedVet approved

    Stanozolol is derived from testosterone, and has been abused by several high profile professional athletes.

  4. Drug

    Leronlimab

    go.drugbank.com/drugs/DB05941
    Investigational

    [L12684] It was first described in the literature in 2001.[A3922] This antibody binds to CCR5, which may be useful in treating HIV, cancers, and severely ill COVID-19 patients.[A192846,A192858,L12684]

  5. Drug

    Enalaprilat

    go.drugbank.com/drugs/DB09477
    ApprovedInvestigational

    Enalaprilat is poorly orally available and is therefore only available as an intravenous injection for the treatment of hypertension when oral therapy is not possible. … Enalaprilat was originally created to overcome the limitations of the first ACE inhibitor, captopril, which had numerous side effects and left a metallic taste in the mouth.

  6. Drug

    Pegcetacoplan

    go.drugbank.com/drugs/DB16694
    ApprovedInvestigational

    [A235000] Pegcetacoplan for subcutaneous use was granted FDA approval on 14 May 2021. … [A235000,A235005] Pegcetacoplan was developed out of a need for an inhibitor of complement mediated hemolysis further upstream of C5.

  7. Drug

    Delandistrogene moxeparvovec

    go.drugbank.com/drugs/DB16802
    ApprovedInvestigational

    It was granted accelerated approval by the FDA on June 22, 2023, as the first gene therapy to treat Duchenne Muscular Dystrophy (DMD).

  8. Drug

    Propafenone

    go.drugbank.com/drugs/DB01182
    ApprovedInvestigational

    It also has weak beta-blocking activity. The drug is generally well tolerated.

  9. Drug

    Potassium bicarbonate

    go.drugbank.com/drugs/DB11098
    ApprovedInvestigational

    [L1836] This FDA denomination classifies potassium bicarbonate as a GRAS ingredient.[L1837] … It is used in medicine as an antacid.[T141] It is registered in the FDA under the section of suitable, safe and effective ingredients for OTC antacids.

  10. Drug

    Technetium Tc-99m exametazime

    go.drugbank.com/drugs/DB09163
    Approved

    Exametazime, also known as hexamethylpropyleneamine oxime or HMPAO, acts as a chelating agent for the Tc-99m radioisotope.